Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases

Clinical Utility Evaluation of a Surgical Sequencing Decision-Support Software in Simulated Cases of Colorectal Liver Metastases: A Multicenter Prospective Study (COLORS-Validate Study)

This study evaluates a surgical decision-support software designed to assist physicians in selecting the optimal surgical sequence for patients with colorectal cancer liver metastases.

In this multicenter prospective simulation study, participating surgeons from multiple centers will review standardized clinical case scenarios. For each case, physicians will first make a surgical sequencing decision based on their own clinical judgment. They will then review the recommendation provided by the decision-support software and make a second decision if they choose to revise their initial plan.

The study will assess whether the software influences clinical decision-making, including changes in surgical strategy, decision confidence, decision time, and agreement with software recommendations. Physician user experience will also be evaluated using standardized questionnaires, including system usability and cognitive workload scales.

The goal of this study is to determine the clinical utility and usability of the decision-support software in improving surgical decision-making consistency and supporting clinical reasoning in colorectal liver metastases cases.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

The selection of surgical sequencing-whether to resect the primary tumor first or the liver metastases first-in patients with colorectal cancer liver metastases (CRLM) undergoing synchronous resection represents a critical and highly complex decision in current clinical practice. With the advancement of systemic therapies and surgical techniques, an increasing number of patients with initially unresectable CRLM have gained the opportunity for surgical treatment. However, due to substantial heterogeneity among patients in terms of tumor burden, biological behavior of the disease, and overall physical condition, no unified standard currently exists for determining the optimal surgical sequence. Existing studies comparing different surgical strategies have yielded inconsistent prognostic results, and most are based on retrospective analyses lacking consistent conclusions and clear stratification criteria. Consequently, in real-world clinical practice, such decisions rely heavily on physician experience and institutional preference, resulting in considerable inter-physician variability and uncertainty. This scenario, characterized by the absence of a clearly optimal strategy, renders the decision-making process inherently a form of decision-making under uncertainty.

Based on this context, we previously developed, using multicenter retrospective data, two multi-outcome predictive models corresponding to different surgical strategies. These models integrate postoperative major complications, Comprehensive Complication Index (CCI), progression-free survival (PFS), and overall survival (OS), and have been externally validated. However, in real-world clinical decision-making, the central challenge faced by surgeons is not merely the prediction of a single outcome, but rather the need to balance multiple competing outcomes. For example, one surgical strategy may be associated with a lower risk of postoperative complications but limited long-term survival benefit, whereas another may involve higher perioperative risk in exchange for improved oncological outcomes. This inherent tension among multidimensional outcomes transforms clinical decision-making into a multi-objective decision-making problem, rather than a simple comparison of a single endpoint.

In current practice, such trade-offs across outcomes are typically based on physicians' experiential judgment, whereby the relative importance of different outcomes is implicitly weighted. However, this weighting process lacks explicit representation and standardized criteria, and is prone to influence by individual experience, risk preference, and institutional norms, thereby leading to substantial variability and inconsistency in decision-making. To address this key limitation, the present study further constructs a structured multi-outcome weighting framework using the Delphi method combined with the analytic hierarchy process (AHP). This approach establishes the relative importance of different clinical outcomes through expert consensus and translates it into a quantifiable weighting system, thereby enabling the integration of multidimensional predictive results into a comparable composite score. Based on this framework, we developed a decision-support software system capable of simultaneously providing individualized multi-outcome predictions and composite reference scores, transforming the previously experience-dependent implicit trade-off process into a transparent, interpretable, and standardized decision-support process.

Nevertheless, the establishment of predictive models and weighting frameworks does not necessarily translate into practical clinical value. For decision-support systems, focusing solely on predictive performance is insufficient to reflect their real-world clinical utility. More importantly, it is necessary to evaluate whether such systems can influence physician decision-making behavior under uncertainty, reduce unnecessary variability, and provide a structured reference framework for decision-making. In addition, because clinical decision-making involves counterfactual comparisons (i.e., potential outcomes under alternative strategies for the same patient cannot be simultaneously observed), traditional outcome-based evaluation methods have inherent limitations. Therefore, it is necessary to adopt a model-informed standardized reference framework to evaluate the impact of AI assistance at the level of decision behavior.

Based on the above considerations, this study adopts a multicenter, prospective crossover simulation design to systematically evaluate the clinical utility of the decision-support system in a standardized setting. The evaluation focuses on the following two dimensions:

  1. From a scientific decision perspective: whether the system alters physician decision behavior, improves decision consistency, and reduces variability;
  2. From a human factors perspective: whether the system affects cognitive load, decision confidence, and user experience.

This study extends AI evaluation beyond predictive performance toward its influence on decision-making behavior, with a particular focus on the human-AI collaborative decision-making process in uncertain clinical scenarios.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

12

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Tak

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

This study will enroll physicians from three tertiary academic medical centers in China, including hepatobiliary surgeons and colorectal surgeons with varying levels of clinical experience. Participants will be required to complete standardized simulation-based case evaluations involving surgical decision-making for colorectal cancer liver metastases. The study aims to assess changes in decision-making behavior, confidence, and usability of a decision-support software system.

Opis

Inclusion Criteria:

  • Licensed physicians specializing in hepatobiliary surgery or colorectal surgery
  • At least 1 year of clinical experience after graduation
  • Willing to participate in the simulation-based decision-making study
  • Practicing at one of the participating tertiary academic hospitals

Exclusion Criteria:

  • Not actively involved in clinical surgical decision-making
  • Unable to complete all required simulation sessions
  • Prior involvement in the development of the decision-support software

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Unaided Clinical Decision-Making
Physicians make surgical sequencing decisions based on routine clinical judgment without decision-support software.
Usual Clinical Decision-Making (Without Decision Support Software)
Decision-Support Software-Assisted Decision-Making
Physicians make surgical sequencing decisions after reviewing recommendations from the decision-support software.
Physicians make surgical sequencing decisions after reviewing recommendations generated by the decision-support software, including weighted scores and predicted outcomes.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Surgical Decision-Making Between Software-Assisted and Non-Assisted Conditions
Ramy czasowe: During each simulated case evaluation session
The primary outcome is the proportion of cases in which physicians change their surgical sequencing decision after reviewing decision-support software recommendations compared with their initial unaided decision.
During each simulated case evaluation session

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Software utilization outcomes
Ramy czasowe: During each simulated case evaluation session
Software adoption rate (agreement between final decision and software recommendation); Post-change adoption rate among changed decisions
During each simulated case evaluation session
Decision performance outcomes
Ramy czasowe: During each simulated case evaluation session
Decision-making time (seconds per case); Inter-group comparison between unaided and software-assisted conditions
During each simulated case evaluation session
Human factors outcomes
Ramy czasowe: During each simulated case evaluation session
Decision confidence score (5-point Likert scale)
During each simulated case evaluation session

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Krzesło do nauki: Hong Zhao, MD, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 września 2026

Zakończenie podstawowe (Szacowany)

30 września 2026

Ukończenie studiów (Szacowany)

30 października 2026

Daty rejestracji na studia

Pierwszy przesłany

23 lipca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 sierpnia 2026

Pierwszy wysłany (Rzeczywisty)

12 sierpnia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 sierpnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 sierpnia 2026

Ostatnia weryfikacja

1 sierpnia 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • NCC-023039

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data will not be publicly shared because of participant confidentiality, institutional data-protection requirements, and the potential risk of re-identification given the characteristics and size of the study population. Aggregate study results will be reported in peer-reviewed publications.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .